Lexeo Therapeutics, Inc. (LXEO)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$2.80-3.11%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Lexeo Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.336
Annual ending 2026-12-31
Revenue	—	0
EPS	—	-1.189
Annual ending 2027-12-31
Revenue	—	6.88M
EPS	—	-1.336

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Reduce losses and improve earnings over next two years	A supporting condition in Lexeo Therapeutics, Inc.'s published investment case. The stated target is EPS loss narrows from -$1.14 in 2026 to less negative in 2027.	Broken	EPS loss worsens beyond -$1.34 in 2027	Diluted EPS: $-0.30 per share FY2026-Q2; GAAP. Published target: EPS loss narrows from -$1.14 in 2026 to less negative in 2027. Target period is not explicitly aligned with this observation. Source published Aug 12, 2026-0.3 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: acf732cf-7b92-432d-b20d-bbb6bc42eb40. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Maintain cash, cash equivalents, and investments to support operations into 2028	A primary condition in Lexeo Therapeutics, Inc.'s published investment case. The stated target is >= $227.6 million cash and equivalents.	Intact	cash falls below $200 million before 2028	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Provide regulatory updates on LX2006 for Friedreich ataxia cardiomyopathy	It has regulatory progress on LX2006.	Intact	No regulatory updates or delays in LX2006 approval process	Qualitative: Regulatory pathway confirmed Seeking Alpha article confirms LX2006 has a viable regulatory pathway and timeline, reinforcing the thesis. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-1.34

$-1.28 → $-1.34 · observed estimates

FY2027 revenue$0.01B

$0.01B → $0.01B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-1.28	$6,875,000	7 / 6
2026-07-25	$-1.28	$6,875,000	7 / 6
2026-07-26	$-1.28	$6,875,000	7 / 6
2026-07-27	$-1.28	$6,875,000	7 / 6
2026-07-28	$-1.28	$6,875,000	7 / 6
2026-07-29	$-1.28	$6,875,000	7 / 6
2026-07-30	$-1.34	$6,111,110	8 / 9
2026-07-31	$-1.34	$6,111,110	8 / 9
2026-08-01	$-1.28	$6,875,000	7 / 6
2026-08-02	$-1.34	$6,111,110	8 / 9
2026-08-03	$-1.34	$6,111,110	8 / 9
2026-08-04	$-1.34	$6,111,110	8 / 9
2026-08-05	$-1.28	$6,875,000	7 / 6
2026-08-06	$-1.28	$6,875,000	7 / 6
2026-08-07	$-1.28	$6,875,000	7 / 6
2026-08-08	$-1.34	$6,111,110	8 / 9
2026-08-09	$-1.34	$6,111,110	8 / 9
2026-08-10	$-1.28	$6,875,000	7 / 6
2026-08-12	$-1.34	$6,111,110	8 / 9
2026-08-13	$-1.34	$6,111,110	8 / 9
2026-08-14	$-1.28	$6,875,000	7 / 6
2026-08-15	$-1.28	$6,875,000	7 / 6
2026-08-16	$-1.28	$6,875,000	7 / 6
2026-08-17	$-1.28	$6,875,000	7 / 6
2026-08-18	$-1.28	$6,875,000	7 / 6
2026-08-19	$-1.28	$6,875,000	7 / 6
2026-08-20	$-1.37	$6,875,000	7 / 6
2026-08-21	$-1.37	$6,875,000	7 / 6
2026-08-22	$-1.37	$6,875,000	7 / 6
2026-08-23	$-1.37	$6,875,000	7 / 6
2026-08-24	$-1.37	$6,875,000	7 / 6
2026-08-25	$-1.37	$6,875,000	7 / 6
2026-08-26	$-1.37	$6,875,000	7 / 6
2026-08-27	$-1.37	$6,875,000	7 / 6
2026-08-28	$-1.37	$6,875,000	7 / 6
2026-08-29	$-1.37	$6,875,000	7 / 6
2026-08-30	$-1.37	$6,875,000	7 / 6
2026-08-31	$-1.37	$6,875,000	7 / 6
2026-09-01	$-1.37	$6,875,000	7 / 6
2026-09-02	$-1.37	$6,875,000	7 / 6
2026-09-03	$-1.37	$6,875,000	7 / 6
2026-09-04	$-1.37	$6,875,000	7 / 6
2026-09-05	$-1.37	$6,875,000	7 / 6
2026-09-06	$-1.37	$6,875,000	7 / 6
2026-09-07	$-1.37	$6,875,000	7 / 6
2026-09-08	$-1.37	$6,875,000	7 / 6
2026-09-09	$-1.37	$6,875,000	7 / 6
2026-09-10	$-1.37	$6,875,000	7 / 6
2026-09-11	$-1.37	$6,875,000	7 / 6
2026-09-12	$-1.37	$6,875,000	7 / 6
2026-09-13	$-1.37	$6,875,000	7 / 6
2026-09-14	$-1.37	$6,875,000	7 / 6
2026-09-15	$-1.37	$6,875,000	7 / 6
2026-09-16	$-1.37	$6,875,000	7 / 6
2026-09-17	$-1.37	$6,875,000	7 / 6
2026-09-18	$-1.37	$6,875,000	7 / 6
2026-09-19	$-1.37	$6,875,000	7 / 6
2026-09-20	$-1.37	$6,875,000	7 / 6
2026-09-21	$-1.37	$6,875,000	7 / 6
2026-09-22	$-1.37	$6,875,000	7 / 6
2026-09-23	$-1.37	$6,875,000	7 / 6
2026-09-24	$-1.34	$6,875,000	7 / 6
2026-09-25	$-1.34	$6,875,000	7 / 6
2026-09-26	$-1.34	$6,875,000	7 / 6
2026-09-27	$-1.34	$6,875,000	7 / 6
2026-09-28	$-1.34	$6,875,000	7 / 6
2026-09-29	$-1.34	$6,875,000	7 / 6
2026-09-30	$-1.34	$6,875,000	7 / 6
2026-10-01	$-1.34	$6,875,000	7 / 6
2026-10-02	$-1.34	$6,875,000	7 / 6
2026-10-03	$-1.34	$6,875,000	7 / 6
2026-10-04	$-1.34	$6,875,000	7 / 6
2026-10-05	$-1.34	$6,875,000	7 / 6
2026-10-06	$-1.34	$6,875,000	7 / 6
2026-10-07	$-1.34	$6,875,000	7 / 6
2026-10-08	$-1.34	$6,875,000	7 / 6
2026-10-09	$-1.34	$6,875,000	7 / 6
2026-10-10	$-1.34	$6,875,000	7 / 6
2026-10-11	$-1.34	$6,875,000	7 / 6
2026-10-12	$-1.34	$6,875,000	7 / 6
2026-10-13	$-1.34	$6,875,000	7 / 6
2026-10-14	$-1.34	$6,875,000	7 / 6
2026-10-15	$-1.34	$6,875,000	7 / 6
2026-10-16	$-1.34	$6,875,000	7 / 6
2026-10-17	$-1.34	$6,875,000	7 / 6
2026-10-18	$-1.34	$6,875,000	7 / 6
2026-10-19	$-1.34	$6,875,000	7 / 6
2026-10-20	$-1.34	$6,875,000	7 / 6
2026-10-21	$-1.34	$6,875,000	7 / 6
2026-10-22	$-1.34	$6,875,000	7 / 6
2026-10-23	$-1.34	$6,875,000	7 / 6
2026-10-24	$-1.34	$6,875,000	7 / 6

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	11	0	0
2026-06-01	10	0	0
2026-07-01	10	0	0
2026-08-01	10	0	0
2026-09-01	10	0	0
2026-10-01	10	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 10 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Reduce losses and improve earnings over next two yearsPublished status: Broken
Maintain cash, cash equivalents, and investments to support operations into 2028Direct metric needs a verified mapping

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.7%Typical daily move · historical

Downside history

-75.3%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Lexeo Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative, clinical-stage biotechnology thesis, where the case depends on trial progress and future regulatory steps rather than current profits. The thesis is on watch: management is on track with the LX2006 trial, but performance is weak, management execution has been volatile, and overall confidence is low.

What's priced into Lexeo Therapeutics, Inc.

The evidence does not include a valuation measure or a clear account of what market expectations already assume, so whether LXEO looks cheap or expensive versus peers is unclear. The market-expectations gap cannot be assessed from this snapshot.

What the fundamentals likely do

Near term, results remain weak and the risk of a miss is elevated; the next company update is an important check on execution. Over the multi-year view, LX2006 enrollment has started, with topline trial data expected in the second half of 2027 and a regulatory submission planned for the first half of 2028. Cash declined modestly through 2026-Q2, while management says runway extends into 2028; the acquisition adds to the platform but also adds execution demands.

What Lexeo Therapeutics, Inc. hinges on

The central swing factor is whether LX2006 advances on schedule and produces data that support the planned regulatory path. A guidance cut or further weakening in jobs data would add risk, while stronger results and guidance from major healthcare peers could support sector momentum. The Mantle acquisition’s progress and its fit within the stated cash runway also matter.

Bottom line

Over the next 1 to 3 years, LXEO remains a high-risk, event-driven long-term thesis with tangible trial progress but limited evidence of financial strength. The thesis hinges on clinical execution, cash discipline, and whether the new platform expansion delivers progress without disrupting the planned runway. Not investment advice.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.336
Annual ending 2026-12-31
Revenue	—	0
EPS	—	-1.189
Annual ending 2027-12-31
Revenue	—	6.88M
EPS	—	-1.336

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-1.34

$-1.28 → $-1.34 · observed estimates

FY2027 revenue$0.01B

$0.01B → $0.01B · observed estimates

Exact estimates & source dates

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-1.28	$6,875,000	7 / 6
2026-07-25	$-1.28	$6,875,000	7 / 6
2026-07-26	$-1.28	$6,875,000	7 / 6
2026-07-27	$-1.28	$6,875,000	7 / 6
2026-07-28	$-1.28	$6,875,000	7 / 6
2026-07-29	$-1.28	$6,875,000	7 / 6
2026-07-30	$-1.34	$6,111,110	8 / 9
2026-07-31	$-1.34	$6,111,110	8 / 9
2026-08-01	$-1.28	$6,875,000	7 / 6
2026-08-02	$-1.34	$6,111,110	8 / 9
2026-08-03	$-1.34	$6,111,110	8 / 9
2026-08-04	$-1.34	$6,111,110	8 / 9
2026-08-05	$-1.28	$6,875,000	7 / 6
2026-08-06	$-1.28	$6,875,000	7 / 6
2026-08-07	$-1.28	$6,875,000	7 / 6
2026-08-08	$-1.34	$6,111,110	8 / 9
2026-08-09	$-1.34	$6,111,110	8 / 9
2026-08-10	$-1.28	$6,875,000	7 / 6
2026-08-12	$-1.34	$6,111,110	8 / 9
2026-08-13	$-1.34	$6,111,110	8 / 9
2026-08-14	$-1.28	$6,875,000	7 / 6
2026-08-15	$-1.28	$6,875,000	7 / 6
2026-08-16	$-1.28	$6,875,000	7 / 6
2026-08-17	$-1.28	$6,875,000	7 / 6
2026-08-18	$-1.28	$6,875,000	7 / 6
2026-08-19	$-1.28	$6,875,000	7 / 6
2026-08-20	$-1.37	$6,875,000	7 / 6
2026-08-21	$-1.37	$6,875,000	7 / 6
2026-08-22	$-1.37	$6,875,000	7 / 6
2026-08-23	$-1.37	$6,875,000	7 / 6
2026-08-24	$-1.37	$6,875,000	7 / 6
2026-08-25	$-1.37	$6,875,000	7 / 6
2026-08-26	$-1.37	$6,875,000	7 / 6
2026-08-27	$-1.37	$6,875,000	7 / 6
2026-08-28	$-1.37	$6,875,000	7 / 6
2026-08-29	$-1.37	$6,875,000	7 / 6
2026-08-30	$-1.37	$6,875,000	7 / 6
2026-08-31	$-1.37	$6,875,000	7 / 6
2026-09-01	$-1.37	$6,875,000	7 / 6
2026-09-02	$-1.37	$6,875,000	7 / 6
2026-09-03	$-1.37	$6,875,000	7 / 6
2026-09-04	$-1.37	$6,875,000	7 / 6
2026-09-05	$-1.37	$6,875,000	7 / 6
2026-09-06	$-1.37	$6,875,000	7 / 6
2026-09-07	$-1.37	$6,875,000	7 / 6
2026-09-08	$-1.37	$6,875,000	7 / 6
2026-09-09	$-1.37	$6,875,000	7 / 6
2026-09-10	$-1.37	$6,875,000	7 / 6
2026-09-11	$-1.37	$6,875,000	7 / 6
2026-09-12	$-1.37	$6,875,000	7 / 6
2026-09-13	$-1.37	$6,875,000	7 / 6
2026-09-14	$-1.37	$6,875,000	7 / 6
2026-09-15	$-1.37	$6,875,000	7 / 6
2026-09-16	$-1.37	$6,875,000	7 / 6
2026-09-17	$-1.37	$6,875,000	7 / 6
2026-09-18	$-1.37	$6,875,000	7 / 6
2026-09-19	$-1.37	$6,875,000	7 / 6
2026-09-20	$-1.37	$6,875,000	7 / 6
2026-09-21	$-1.37	$6,875,000	7 / 6
2026-09-22	$-1.37	$6,875,000	7 / 6
2026-09-23	$-1.37	$6,875,000	7 / 6
2026-09-24	$-1.34	$6,875,000	7 / 6
2026-09-25	$-1.34	$6,875,000	7 / 6
2026-09-26	$-1.34	$6,875,000	7 / 6
2026-09-27	$-1.34	$6,875,000	7 / 6
2026-09-28	$-1.34	$6,875,000	7 / 6
2026-09-29	$-1.34	$6,875,000	7 / 6
2026-09-30	$-1.34	$6,875,000	7 / 6
2026-10-01	$-1.34	$6,875,000	7 / 6
2026-10-02	$-1.34	$6,875,000	7 / 6
2026-10-03	$-1.34	$6,875,000	7 / 6
2026-10-04	$-1.34	$6,875,000	7 / 6
2026-10-05	$-1.34	$6,875,000	7 / 6
2026-10-06	$-1.34	$6,875,000	7 / 6
2026-10-07	$-1.34	$6,875,000	7 / 6
2026-10-08	$-1.34	$6,875,000	7 / 6
2026-10-09	$-1.34	$6,875,000	7 / 6
2026-10-10	$-1.34	$6,875,000	7 / 6
2026-10-11	$-1.34	$6,875,000	7 / 6
2026-10-12	$-1.34	$6,875,000	7 / 6
2026-10-13	$-1.34	$6,875,000	7 / 6
2026-10-14	$-1.34	$6,875,000	7 / 6
2026-10-15	$-1.34	$6,875,000	7 / 6
2026-10-16	$-1.34	$6,875,000	7 / 6
2026-10-17	$-1.34	$6,875,000	7 / 6
2026-10-18	$-1.34	$6,875,000	7 / 6
2026-10-19	$-1.34	$6,875,000	7 / 6
2026-10-20	$-1.34	$6,875,000	7 / 6
2026-10-21	$-1.34	$6,875,000	7 / 6
2026-10-22	$-1.34	$6,875,000	7 / 6
2026-10-23	$-1.34	$6,875,000	7 / 6
2026-10-24	$-1.34	$6,875,000	7 / 6

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings